{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:49:20Z","timestamp":1793152160211,"version":"4.5.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Desmoplastic small round cell tumor (DSRCT) is an ultra-rare sarcoma with limited treatment options. Here, we show that comprehensive molecular profiling informs diagnosis and individualized therapy in this disease. We report the results of whole-genome\/exome, transcriptome, and DNA methylome analyses performed in 30 refractory DSRCT patients, complemented by (phospho)proteomic profiling in nine, within a nationwide precision oncology program. In eight patients (27%), DSRCT was diagnosed only after molecular profiling. Although DSRCTs have \u201cquiet\u201d genomes, 28 patients (93%) received 107 molecular-based management recommendations, including assessment of clinical trial eligibility in 17 (57%). Most recommendations are informed by overexpression of tyrosine kinases, SSTR3\/5, and CLDN6, detected in 45%, 33%, and 20% of cases, respectively. Thirteen patients (46%) received recommended therapies, yielding disease control in eight (62%), including three long-lasting responses to pazopanib and trastuzumab deruxtecan, the latter administered based on ERBB2 overexpression in the absence of aberrant ERBB2 kinase activation. These findings demonstrate that multi-omics profiling provides clinically actionable insights for DSRCT management.<\/jats:p>","DOI":"10.1038\/s41467-026-71636-0","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:38:49Z","timestamp":1775741929000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Multi-layered molecular profiling informs the diagnosis and targeted therapy of desmoplastic small round cell tumor"],"prefix":"10.1038","volume":"17","author":[{"given":"Marcus","family":"Renner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1520-1054","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Ole\u015b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagarajan","family":"Paramasivam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8869-1421","authenticated-orcid":false,"given":"Christoph E.","family":"Heilig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Modugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Herremans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"H\u00fcllein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9034-0329","authenticated-orcid":false,"given":"Barbara","family":"Hutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4378-9075","authenticated-orcid":false,"given":"Cihan","family":"Erkut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3332-9166","authenticated-orcid":false,"given":"Andreas","family":"Mock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Krieghoff-Henning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia B.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sakhteman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5401-5553","authenticated-orcid":false,"given":"Matthew","family":"The","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4866-6456","authenticated-orcid":false,"given":"Tony","family":"Prinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panna","family":"Lajer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Baude-M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Beuthien-Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6358-8206","authenticated-orcid":false,"given":"Leonidas","family":"Apostolidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5949-8120","authenticated-orcid":false,"given":"Sebastian","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3670-0602","authenticated-orcid":false,"given":"Melanie","family":"Boerries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian H.","family":"Brandts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0027-7977","authenticated-orcid":false,"given":"Damian T.","family":"Rieke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9131-2389","authenticated-orcid":false,"given":"Frederick","family":"Klauschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Schulze-Osthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2215-2059","authenticated-orcid":false,"given":"Richard F.","family":"Schlenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Berchem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4518-7887","authenticated-orcid":false,"given":"Michael","family":"Allg\u00e4uer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunhild","family":"Mechtersheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1001-103X","authenticated-orcid":false,"given":"Albrecht","family":"Stenzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5081-7869","authenticated-orcid":false,"given":"Daniel B.","family":"Lipka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5896-4086","authenticated-orcid":false,"given":"Matthias","family":"Schlesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9094-1677","authenticated-orcid":false,"given":"Bernhard","family":"Kuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-1908","authenticated-orcid":false,"given":"Arne","family":"Jahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelin","family":"Schr\u00f6ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Heining","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Veronica","family":"Teleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4536-9306","authenticated-orcid":false,"given":"Peter","family":"Horak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3278-4586","authenticated-orcid":false,"given":"Simon","family":"Kreutzfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6041-7049","authenticated-orcid":false,"given":"Daniel","family":"H\u00fcbschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7609-5021","authenticated-orcid":false,"given":"Wolfgang","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4104-1135","authenticated-orcid":false,"given":"Hanno","family":"Glimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7907-4595","authenticated-orcid":false,"given":"Stefan","family":"Fr\u00f6hling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"71636_CR1","doi-asserted-by":"publisher","first-page":"e0246958","DOI":"10.1371\/journal.pone.0246958","volume":"16","author":"G de Pinieux","year":"2021","unstructured":"de Pinieux, G. et al. Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. PLoS ONE 16, e0246958 (2021).","journal-title":"PLoS ONE"},{"key":"71636_CR2","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1002\/cncr.33618","volume":"127","author":"S Stacchiotti","year":"2021","unstructured":"Stacchiotti, S. et al. Ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer 127, 2934\u20132942 (2021).","journal-title":"Cancer"},{"key":"71636_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/00000478-199204000-00010","volume":"16","author":"JR Sawyer","year":"1992","unstructured":"Sawyer, J. R., Tryka, A. F. & Lewis, J. M. A novel reciprocal chromosome translocation t(11;22)(p13;q12) in an intraabdominal desmoplastic small round-cell tumor. Am. J. Surg. Pathol. 16, 411\u2013416 (1992).","journal-title":"Am. J. Surg. Pathol."},{"key":"71636_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0165-4608(93)90105-U","volume":"69","author":"E Rodriguez","year":"1993","unstructured":"Rodriguez, E. et al. A recurring translocation, t(11;22)(p13;q11.2), characterizes intra-abdominal desmoplastic small round-cell tumors. Cancer Genet. Cytogenet. 69, 17\u201321 (1993).","journal-title":"Cancer Genet. Cytogenet."},{"key":"71636_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.semcancer.2005.01.005","volume":"15","author":"WL Gerald","year":"2005","unstructured":"Gerald, W. L. & Haber, D. A. The EWS-WT1 gene fusion in desmoplastic small round cell tumor. Semin Cancer Biol. 15, 197\u2013205 (2005).","journal-title":"Semin Cancer Biol."},{"key":"71636_CR6","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1073\/pnas.92.4.1028","volume":"92","author":"WL Gerald","year":"1995","unstructured":"Gerald, W. L., Rosai, J. & Ladanyi, M. Characterization of the genomic breakpoint and chimeric transcripts in the EWS-WT1 gene fusion of desmoplastic small round cell tumor. Proc. Natl. Acad. Sci. USA 92, 1028\u20131032 (1995).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"71636_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-020-0224-1","volume":"9","author":"JM Gedminas","year":"2020","unstructured":"Gedminas, J. M. et al. Desmoplastic small round cell tumor is dependent on the EWS-WT1 transcription factor. Oncogenesis 9, 41 (2020).","journal-title":"Oncogenesis"},{"key":"71636_CR8","doi-asserted-by":"crossref","unstructured":"Trikalinos, N. A., Chrisinger, J. S. A. & Van Tine, B. A. Common pitfalls in Ewing sarcoma and desmoplastic small round cell tumor diagnosis seen in a study of 115 Cases. Med. Sci. 9, 62 (2021).","DOI":"10.3390\/medsci9040062"},{"key":"71636_CR9","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.1158\/1078-0432.CCR-18-0202","volume":"24","author":"V Subbiah","year":"2018","unstructured":"Subbiah, V. et al. Multimodality treatment of desmoplastic small round cell tumor: chemotherapy and complete cytoreductive surgery improve patient survival. Clin. Cancer Res. 24, 4865\u20134873 (2018).","journal-title":"Clin. Cancer Res."},{"key":"71636_CR10","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1245\/s10434-014-4123-6","volume":"22","author":"C Honor\u00e9","year":"2015","unstructured":"Honor\u00e9, C. et al. Abdominal desmoplastic small round cell tumor: multimodal treatment combining chemotherapy, surgery, and radiotherapy is the best option. Ann. Surg. Oncol. 22, 1073\u20131079 (2015).","journal-title":"Ann. Surg. Oncol."},{"key":"71636_CR11","doi-asserted-by":"crossref","unstructured":"Mello, C. A. et al. Desmoplastic small round cell tumor: a review of main molecular abnormalities and emerging therapy. Cancers 13, 498 (2021).","DOI":"10.3390\/cancers13030498"},{"key":"71636_CR12","doi-asserted-by":"publisher","first-page":"102140","DOI":"10.1016\/j.ctrv.2020.102140","volume":"93","author":"A Hendricks","year":"2021","unstructured":"Hendricks, A., Boerner, K., Germer, C.-T. & Wiegering, A. Desmoplastic small round cell tumors: a review with focus on clinical management and therapeutic options. Cancer Treat. Rev. 93, 102140 (2021).","journal-title":"Cancer Treat. Rev."},{"key":"71636_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00257-9","volume":"6","author":"C-C Wu","year":"2022","unstructured":"Wu, C.-C. et al. Multi-site desmoplastic small round cell tumors are genetically related and immune-cold. NPJ Precis Oncol. 6, 21 (2022).","journal-title":"NPJ Precis Oncol."},{"key":"71636_CR14","first-page":"6868","volume":"61","author":"BS Worley","year":"2001","unstructured":"Worley, B. S. et al. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res. 61, 6868\u20136875 (2001).","journal-title":"Cancer Res."},{"key":"71636_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40880-018-0339-3","volume":"38","author":"A Devecchi","year":"2018","unstructured":"Devecchi, A. et al. The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial-mesenchymal transition, and immune response. Cancer Commun. 38, 70 (2018).","journal-title":"Cancer Commun."},{"key":"71636_CR16","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S1470-2045(23)00282-6","volume":"24","author":"J-Y Blay","year":"2023","unstructured":"Blay, J.-Y. et al. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcS\u00e9 Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial. Lancet Oncol. 24, 892\u2013902 (2023).","journal-title":"Lancet Oncol."},{"key":"71636_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s11523-012-0251-8","volume":"8","author":"A Italiano","year":"2013","unstructured":"Italiano, A., Kind, M., Cioffi, A., Maki, R. G. & Bui, B. Clinical activity of sunitinib in patients with advanced desmoplastic round cell tumor: a case series. Target Oncol. 8, 211\u2013213 (2013).","journal-title":"Target Oncol."},{"key":"71636_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4135-x","volume":"18","author":"C Shi","year":"2018","unstructured":"Shi, C. et al. Effective treatment of apatinib in desmoplastic small round cell tumor: a case report and literature review. BMC Cancer 18, 338 (2018).","journal-title":"BMC Cancer"},{"key":"71636_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/OTT.S190333","volume":"12","author":"H-M Chen","year":"2019","unstructured":"Chen, H.-M. & Feng, G. Use of anlotinib in intra-abdominal desmoplastic small round cell tumors: a case report and literature review. OncoTargets Ther. 12, 57\u201361 (2019).","journal-title":"OncoTargets Ther."},{"key":"71636_CR20","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1634\/theoncologist.2017-0408","volume":"23","author":"BA Menegaz","year":"2018","unstructured":"Menegaz, B. A. et al. Clinical activity of pazopanib in patients with advanced desmoplastic small round cell tumor. Oncologist 23, 360\u2013366 (2018).","journal-title":"Oncologist"},{"key":"71636_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/2045-3329-4-7","volume":"4","author":"AM Frezza","year":"2014","unstructured":"Frezza, A. M. et al. Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience. Clin. Sarcoma Res. 4, 7 (2014).","journal-title":"Clin. Sarcoma Res."},{"key":"71636_CR22","doi-asserted-by":"crossref","unstructured":"Smith, R. S. et al. Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling. Dis. Model. Mech. 15, dmm047621 (2022).","DOI":"10.1242\/dmm.047621"},{"key":"71636_CR23","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1158\/1078-0432.CCR-24-1835","volume":"30","author":"T Zhang","year":"2024","unstructured":"Zhang, T. et al. HER2 antibody-drug conjugates are active against desmoplastic small round cell tumor. Clin. Cancer Res. 30, 4701\u20134713 (2024).","journal-title":"Clin. Cancer Res."},{"key":"71636_CR24","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","volume":"29","author":"F Mosele","year":"2023","unstructured":"Mosele, F. et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat. Med. 29, 2110\u20132120 (2023).","journal-title":"Nat. Med."},{"key":"71636_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam, F. et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J. Clin. Oncol. 42, 47\u201358 (2024).","journal-title":"J. Clin. Oncol."},{"key":"71636_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104133","volume":"10","author":"M Brahmi","year":"2025","unstructured":"Brahmi, M. et al. High expression level of ERBB2 and efficacy of trastuzumab deruxtecan in desmoplastic small round cell tumour: a monocentric case series report. ESMO Open 10, 104133 (2025).","journal-title":"ESMO Open"},{"key":"71636_CR27","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/ijc.30828","volume":"141","author":"P Horak","year":"2017","unstructured":"Horak, P. et al. Precision oncology based on omics data: the NCT Heidelberg experience. Int J. Cancer 141, 877\u2013886 (2017).","journal-title":"Int J. Cancer"},{"key":"71636_CR28","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1158\/2159-8290.CD-21-0126","volume":"11","author":"P Horak","year":"2021","unstructured":"Horak, P. et al. Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Cancer Discov. 11, 2780\u20132795 (2021).","journal-title":"Cancer Discov."},{"key":"71636_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20603-4","volume":"12","author":"C Koelsche","year":"2021","unstructured":"Koelsche, C. et al. Sarcoma classification by DNA methylation profiling. Nat. Commun. 12, 498 (2021).","journal-title":"Nat. Commun."},{"key":"71636_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00458-w","volume":"7","author":"A Mock","year":"2023","unstructured":"Mock, A. et al. NCT\/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology. npj Precis. Oncol. 7, 109 (2023).","journal-title":"npj Precis. Oncol."},{"key":"71636_CR31","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/gcc.22987","volume":"61","author":"P Horak","year":"2022","unstructured":"Horak, P. et al. Assigning evidence to actionability: an introduction to variant interpretation in precision cancer medicine. Genes Chromosom. Cancer 61, 303\u2013313 (2022).","journal-title":"Genes Chromosom. Cancer"},{"key":"71636_CR32","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1158\/1541-7786.MCR-20-0722","volume":"19","author":"EK Slotkin","year":"2021","unstructured":"Slotkin, E. K. et al. Comprehensive molecular profiling of desmoplastic small round cell tumor. Mol. Cancer Res. 19, 1146\u20131155 (2021).","journal-title":"Mol. Cancer Res."},{"key":"71636_CR33","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2174\/138945009788680428","volume":"10","author":"M Duman-Scheel","year":"2009","unstructured":"Duman-Scheel, M. Netrin and DCC: axon guidance regulators at the intersection of nervous system development and cancer. Curr. Drug Targets 10, 602\u2013610 (2009).","journal-title":"Curr. Drug Targets"},{"key":"71636_CR34","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1136\/gutjnl-2013-306704","volume":"63","author":"P Mehlen","year":"2014","unstructured":"Mehlen, P. & Tauszig-Delamasure, S. Dependence receptors and colorectal cancer. Gut 63, 1821\u20131829 (2014).","journal-title":"Gut"},{"key":"71636_CR35","first-page":"1443","volume":"52","author":"R Zeng","year":"2018","unstructured":"Zeng, R. et al. EPB41L3 is a potential tumor suppressor gene and prognostic indicator in esophageal squamous cell carcinoma. Int J. Oncol. 52, 1443\u20131454 (2018).","journal-title":"Int J. Oncol."},{"key":"71636_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1582738","volume":"15","author":"K Zhou","year":"2025","unstructured":"Zhou, K. et al. SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance. Front. Oncol. 15, 1582738 (2025).","journal-title":"Front. Oncol."},{"key":"71636_CR37","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1038\/s41388-024-03094-1","volume":"43","author":"H Onji","year":"2024","unstructured":"Onji, H. et al. Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks. Oncogene 43, 2475\u20132489 (2024).","journal-title":"Oncogene"},{"key":"71636_CR38","doi-asserted-by":"publisher","first-page":"S762","DOI":"10.1016\/j.annonc.2022.07.615","volume":"33","author":"CE Heilig","year":"2022","unstructured":"Heilig, C. E. et al. 487P randomized phase II study of trabectedin\/olaparib compared to physician\u2019s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies. Ann. Oncol. 33, S762\u2013S763 (2022).","journal-title":"Ann. Oncol."},{"key":"71636_CR39","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/gcc.22955","volume":"60","author":"S Sydow","year":"2021","unstructured":"Sydow, S. et al. Genomic and transcriptomic characterization of desmoplastic small round cell tumors. Genes Chromosom. Cancer 60, 595\u2013603 (2021).","journal-title":"Genes Chromosom. Cancer"},{"key":"71636_CR40","doi-asserted-by":"publisher","first-page":"E489","DOI":"10.1210\/jc.2013-3486","volume":"99","author":"JK Bickmann","year":"2014","unstructured":"Bickmann, J. K. et al. Phenotypic variability and risk of malignancy in SDHC-linked paragangliomas: lessons from three unrelated cases with an identical germline mutation (p.Arg133*). J. Clin. Endocrinol. Metab. 99, E489\u2013E496 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"71636_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44360-2","volume":"15","author":"J Sch\u00f6pf","year":"2024","unstructured":"Sch\u00f6pf, J. et al. Multi-omic and functional analysis for classification and treatment of sarcomas with FUS-TFCP2 or EWSR1-TFCP2 fusions. Nat. Commun. 15, 51 (2024).","journal-title":"Nat. Commun."},{"key":"71636_CR42","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen, A. et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat. Med. 29, 2844\u20132853 (2023).","journal-title":"Nat. Med."},{"key":"71636_CR43","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2024.42.16_suppl.3068","volume":"42","author":"A Schneider","year":"2024","unstructured":"Schneider, A. et al. Therapeutic implications of phosphoproteomics in molecular cancer diagnostics. J. Clin. Oncol. 42, 3068\u20133068 (2024).","journal-title":"J. Clin. Oncol."},{"key":"71636_CR44","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41392-019-0049-6","volume":"4","author":"ATJ Lee","year":"2019","unstructured":"Lee, A. T. J., Jones, R. L. & Huang, P. H. Pazopanib in advanced soft tissue sarcomas. Signal Transduct. Target Ther. 4, 16 (2019).","journal-title":"Signal Transduct. Target Ther."},{"key":"71636_CR45","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.annonc.2020.08.2335","volume":"31","author":"J Laskin","year":"2020","unstructured":"Laskin, J. et al. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents. Ann. Oncol. 31, 1693\u20131703 (2020).","journal-title":"Ann. Oncol."},{"key":"71636_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100310","volume":"6","author":"CE Heilig","year":"2021","unstructured":"Heilig, C. E. et al. Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial. ESMO Open 6, 100310 (2021).","journal-title":"ESMO Open"},{"key":"71636_CR47","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/cac2.70015","volume":"45","author":"FH Geyer","year":"2025","unstructured":"Geyer, F. H. et al. Comprehensive DSRCT multi-omics analyses unveil CACNA2D2 as a diagnostic hallmark and super-enhancer-driven EWSR1::WT1 signature gene. Cancer Commun. 45, 702\u2013708 (2025).","journal-title":"Cancer Commun."},{"key":"71636_CR48","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.annonc.2022.07.008","volume":"33","author":"A Jahn","year":"2022","unstructured":"Jahn, A. et al. Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers. Ann. Oncol. 33, 1186\u20131199 (2022).","journal-title":"Ann. Oncol."},{"key":"71636_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-016-0092-0","volume":"10","author":"EN Ferreira","year":"2016","unstructured":"Ferreira, E. N. et al. A genomic case study of desmoplastic small round cell tumor: comprehensive analysis reveals insights into potential therapeutic targets and development of a monitoring tool for a rare and aggressive disease. Hum. Genom. 10, 36 (2016).","journal-title":"Hum. Genom."},{"key":"71636_CR50","volume":"45","author":"CE Heilig","year":"2025","unstructured":"Heilig, C. E. et al. Rationale and design of the PAMSARC (pasireotide as maintenance treatment with monthly deep intramuscular injection in SSTR2\/3\/5-expressing synovial sarcoma and desmoplastic small round cell tumor) multicenter phase 2 trial. Cancer Treat. Res. Commun. 45, 100986 (2025).","journal-title":"Cancer Treat. Res. Commun."},{"key":"71636_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59779-y","volume":"16","author":"S M\u00fcller-Dott","year":"2025","unstructured":"M\u00fcller-Dott, S. et al. Comprehensive evaluation of phosphoproteomic-based kinase activity inference. Nat. Commun. 16, 4771 (2025).","journal-title":"Nat. Commun."},{"key":"71636_CR52","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.semcancer.2022.05.011","volume":"84","author":"WTA van der Graaf","year":"2022","unstructured":"van der Graaf, W. T. A., Tesselaar, M. E. T., McVeigh, T. P., Oyen, W. J. G. & Fr\u00f6hling, S. Biology-guided precision medicine in rare cancers: lessons from sarcomas and neuroendocrine tumours. Semin Cancer Biol. 84, 228\u2013241 (2022).","journal-title":"Semin Cancer Biol."},{"key":"71636_CR53","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","volume":"28","author":"DD Von Hoff","year":"2010","unstructured":"Von Hoff, D. D. et al. Pilot study using molecular profiling of patients\u2019 tumors to find potential targets and select treatments for their refractory cancers. J. Clin. Oncol. 28, 4877\u20134883 (2010).","journal-title":"J. Clin. Oncol."},{"key":"71636_CR54","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1200\/JCO.2014.60.7341","volume":"33","author":"J Tabernero","year":"2015","unstructured":"Tabernero, J. et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 33, 3401\u20133408 (2015).","journal-title":"J. Clin. Oncol."},{"key":"71636_CR55","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1089\/gtmb.2018.0326","volume":"23","author":"Y-H Su","year":"2019","unstructured":"Su, Y.-H. An old concept with a new twist. Genet. Test. Mol. Biomark. 23, 230\u2013232 (2019).","journal-title":"Genet. Test. Mol. Biomark."},{"key":"71636_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00865-1","volume":"9","author":"BP Gladstone","year":"2025","unstructured":"Gladstone, B. P. et al. Systematic review and meta-analysis of molecular tumor board data on clinical effectiveness and evaluation gaps. npj Precis. Oncol. 9, 96 (2025).","journal-title":"npj Precis. Oncol."},{"key":"71636_CR57","doi-asserted-by":"publisher","DOI":"10.1177\/1179554920987107","volume":"15","author":"H Jeong","year":"2021","unstructured":"Jeong, H. et al. The role and clinical effectiveness of multiline chemotherapy in advanced desmoplastic small round cell tumor. Clin. Med Insights Oncol. 15, 1179554920987107 (2021).","journal-title":"Clin. Med Insights Oncol."},{"key":"71636_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s13569-017-0076-4","volume":"7","author":"S B\u00e9trian","year":"2017","unstructured":"B\u00e9trian, S. et al. Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC\u2019s). Clin. Sarcoma Res. 7, 10 (2017).","journal-title":"Clin. Sarcoma Res."},{"key":"71636_CR59","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/S1470-2045(17)30445-X","volume":"18","author":"G Gatta","year":"2017","unstructured":"Gatta, G. et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol. 18, 1022\u20131039 (2017).","journal-title":"Lancet Oncol."},{"key":"71636_CR60","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1093\/bioinformatics\/btv098","volume":"31","author":"A Tarasov","year":"2015","unstructured":"Tarasov, A., Vilella, A. J., Cuppen, E., Nijman, I. J. & Prins, P. Sambamba: fast processing of NGS alignment formats. Bioinformatics 31, 2032\u20132034 (2015).","journal-title":"Bioinformatics"},{"key":"71636_CR61","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jbiotec.2017.08.006","volume":"261","author":"E Reisinger","year":"2017","unstructured":"Reisinger, E. et al. OTP: an automatized system for managing and processing NGS data. J. Biotechnol. 261, 53\u201362 (2017).","journal-title":"J. Biotechnol."},{"key":"71636_CR62","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/ng.2682","volume":"45","author":"DTW Jones","year":"2013","unstructured":"Jones, D. T. W. et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat. Genet 45, 927\u2013932 (2013).","journal-title":"Nat. Genet"},{"key":"71636_CR63","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature11284","volume":"488","author":"DTW Jones","year":"2012","unstructured":"Jones, D. T. W. et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 488, 100\u2013105 (2012).","journal-title":"Nature"},{"key":"71636_CR64","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/ng.3036","volume":"46","author":"A Rimmer","year":"2014","unstructured":"Rimmer, A. et al. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. Nat. Genet. 46, 912\u2013918 (2014).","journal-title":"Nat. Genet."},{"key":"71636_CR65","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00401-017-1715-9","volume":"134","author":"F Sahm","year":"2017","unstructured":"Sahm, F. et al. Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature. Acta Neuropathol. 134, 155\u2013158 (2017).","journal-title":"Acta Neuropathol."},{"key":"71636_CR66","doi-asserted-by":"publisher","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich, E., Shain, A. H., Botton, T. & Bastian, B. C. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput. Biol. 12, e1004873 (2016).","journal-title":"PLoS Comput. Biol."},{"key":"71636_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0973-5","volume":"17","author":"BS Pedersen","year":"2016","unstructured":"Pedersen, B. S., Layer, R. M. & Quinlan, A. R. Vcfanno: fast, flexible annotation of genetic variants. Genome Biol. 17, 118 (2016).","journal-title":"Genome Biol."},{"key":"71636_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren, W. et al. The ensembl variant effect predictor. Genome Biol. 17, 122 (2016).","journal-title":"Genome Biol."},{"key":"71636_CR69","doi-asserted-by":"publisher","first-page":"E5528","DOI":"10.1073\/pnas.1522203113","volume":"113","author":"Y Jiang","year":"2016","unstructured":"Jiang, Y., Qiu, Y., Minn, A. J. & Zhang, N. R. Assessing intratumor heterogeneity and tracking longitudinal and spatial clonal evolutionary history by next-generation sequencing. Proc. Natl. Acad. Sci. USA 113, E5528\u2013E5537 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"71636_CR70","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1038\/s41588-023-01449-0","volume":"55","author":"M Babadi","year":"2023","unstructured":"Babadi, M. et al. GATK-gCNV enables the discovery of rare copy number variants from exome sequencing data. Nat. Genet. 55, 1589\u20131597 (2023).","journal-title":"Nat. Genet."},{"key":"71636_CR71","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 17, 405\u2013424 (2015).","journal-title":"Genet Med."},{"key":"71636_CR72","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1056\/NEJMsr1406261","volume":"372","author":"HL Rehm","year":"2015","unstructured":"Rehm, H. L. et al. ClinGen-the clinical genome resource. N. Engl. J. Med. 372, 2235\u20132242 (2015).","journal-title":"N. Engl. J. Med."},{"key":"71636_CR73","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"71636_CR74","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/gcc.22918","volume":"60","author":"D H\u00fcbschmann","year":"2021","unstructured":"H\u00fcbschmann, D. et al. Analysis of mutational signatures with yet another package for signature analysis. Genes Chromosom. Cancer 60, 314\u2013331 (2021).","journal-title":"Genes Chromosom. Cancer"},{"key":"71636_CR75","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/bioinformatics\/btu049","volume":"30","author":"MJ Aryee","year":"2014","unstructured":"Aryee, M. J. et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics 30, 1363\u20131369 (2014).","journal-title":"Bioinformatics"},{"key":"71636_CR76","first-page":"e22","volume":"45","author":"W Zhou","year":"2017","unstructured":"Zhou, W., Laird, P. W. & Shen, H. Comprehensive characterization, annotation and innovative use of Infinium DNA methylation BeadChip probes. Nucleic Acids Res. 45, e22 (2017).","journal-title":"Nucleic Acids Res."},{"key":"71636_CR77","doi-asserted-by":"crossref","unstructured":"Kaur, D. et al. Comprehensive evaluation of the infinium human methylationEPIC v2 BeadChip. Epigenet. Commun. 3, 6 (2023).","DOI":"10.1186\/s43682-023-00021-5"},{"key":"71636_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-14-293","volume":"14","author":"R Pidsley","year":"2013","unstructured":"Pidsley, R. et al. A data-driven approach to preprocessing Illumina 450K methylation array data. BMC Genom. 14, 293 (2013).","journal-title":"BMC Genom."},{"key":"71636_CR79","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"71636_CR80","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1101\/gr.257246.119","volume":"31","author":"S Uhrig","year":"2021","unstructured":"Uhrig, S. et al. Accurate and efficient detection of gene fusions from RNA sequencing data. Genome Res. 31, 448\u2013460 (2021).","journal-title":"Genome Res."},{"key":"71636_CR81","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41596-018-0082-x","volume":"14","author":"CS Hughes","year":"2019","unstructured":"Hughes, C. S. et al. Single-pot, solid-phase-enhanced sample preparation for proteomics experiments. Nat. Protoc. 14, 68\u201385 (2019).","journal-title":"Nat. Protoc."},{"key":"71636_CR82","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1074\/mcp.TIR119.001385","volume":"18","author":"J Zecha","year":"2019","unstructured":"Zecha, J. et al. TMT labeling for the masses: a robust and cost-efficient, in-solution labeling approach. Mol. Cell Proteom. 18, 1468\u20131478 (2019).","journal-title":"Mol. Cell Proteom."},{"key":"71636_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114272","volume":"43","author":"Y-C Chang","year":"2024","unstructured":"Chang, Y.-C. et al. Decrypting lysine deacetylase inhibitor action and protein modifications by dose-resolved proteomics. Cell Rep. 43, 114272 (2024).","journal-title":"Cell Rep."},{"key":"71636_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13973-x","volume":"11","author":"Y Bian","year":"2020","unstructured":"Bian, Y. et al. Robust, reproducible and quantitative analysis of thousands of proteomes by micro-flow LC-MS\/MS. Nat. Commun. 11, 157 (2020).","journal-title":"Nat. Commun."},{"key":"71636_CR85","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s44320-025-00085-6","volume":"21","author":"S H\u00f6fer","year":"2025","unstructured":"H\u00f6fer, S. et al. Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response. Mol. Syst. Biol. 21, 231\u2013253 (2025).","journal-title":"Mol. Syst. Biol."},{"key":"71636_CR86","doi-asserted-by":"publisher","first-page":"100238","DOI":"10.1016\/j.mcpro.2022.100238","volume":"21","author":"F Hamood","year":"2022","unstructured":"Hamood, F., Bayer, F. P., Wilhelm, M., Kuster, B. & The, M. SIMSI-transfer: software-assisted reduction of missing values in phosphoproteomic and proteomic isobaric labeling data using tandem mass spectrum clustering. Mol. Cell Proteom. 21, 100238 (2022).","journal-title":"Mol. Cell Proteom."},{"key":"71636_CR87","doi-asserted-by":"publisher","first-page":"100437","DOI":"10.1016\/j.mcpro.2022.100437","volume":"21","author":"M The","year":"2022","unstructured":"The, M., Samaras, P., Kuster, B. & Wilhelm, M. Reanalysis of proteomicsDB using an accurate, sensitive, and scalable false discovery rate estimation approach for protein groups. Mol. Cell Proteom. 21, 100437 (2022).","journal-title":"Mol. Cell Proteom."},{"key":"71636_CR88","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1158\/1078-0432.CCR-17-3553","volume":"25","author":"I Isfort","year":"2019","unstructured":"Isfort, I. et al. SS18-SSX-dependent YAP\/TAZ signaling in synovial sarcoma. Clin. Cancer Res. 25, 3718\u20133731 (2019).","journal-title":"Clin. Cancer Res."},{"key":"71636_CR89","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists Guideline Update. J. Clin. Oncol. 41, 3867\u20133872 (2023).","journal-title":"J. Clin. Oncol."},{"key":"71636_CR90","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1002\/ijc.32358","volume":"145","author":"J Leichsenring","year":"2019","unstructured":"Leichsenring, J. et al. Variant classification in precision oncology. Int J. Cancer 145, 2996\u20133010 (2019).","journal-title":"Int J. Cancer"},{"key":"71636_CR91","first-page":"e2200147","volume":"7","author":"S Kreutzfeldt","year":"2023","unstructured":"Kreutzfeldt, S., Horak, P., H\u00fcbschmann, D., Knurr, A. & Fr\u00f6hling, S. National center for tumor diseases precision oncology thesaurus for drugs: a curated database for drugs, drug classes, and drug targets in precision cancer medicine. JCO Clin. Cancer Inf. 7, e2200147 (2023).","journal-title":"JCO Clin. Cancer Inf."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71636-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71636-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71636-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:03:46Z","timestamp":1775750626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71636-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71636"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71636-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6104125\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.A. has had an advisory role and received honoraria from AbbVie and Boehringer Ingelheim. G.M. has had an advisory role and received honoraria from Boehringer Ingelheim. D.B.L. has received honoraria from Infectopharm. B.K. is a co-founder and shareholder of OmicScouts and MSAID. He has no operational role in either company. A.J. has received honoraria from AstraZeneca. C.H. has had an advisory role and received honoraria and research funding from Boehringer Ingelheim, Novartis, and Roche. S.F. has had an advisory role and received honoraria from Illumina. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3397"}}